Scientific EXPERT Act of 2025
Sponsor

Full profile: /officials/M001163
Source: Congress.gov · FEC
Cosponsors (6)
Members who have signed on to support this bill since introduction. Source: Congress.gov.
6 cosponsors on record at Congress.gov. The named list is syncing into Govwatch and will appear here shortly — view on Congress.gov in the meantime.
Latest Action
The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →
Committee Activity
Currently in
- House Committee on Energy and CommerceReferred To · 2025-02-24
Plain-English Summary
Scientific External Process for Educated Review of Therapeutics Act of 2025 or the Scientific EXPERT Act of 2025 This bill requires the Food and Drug Administration (FDA) to facilitate and participate in externally led, science-focused drug development meetings to discuss the development of treatments for rare diseases and conditions. The FDA must enter into an arrangement with the Reagan-Udall Foundation for the FDA under which the foundation agrees to convene such meetings. Meetings must be held at least four times a year, and each meeting must focus on a different rare disease or condition. The foundation must establish a permanent steering committee to review and recommend topics for each meeting. In evaluating potential topics, the committee must consider unmet therapeutic needs, patient population sizes for different diseases and conditions, and whether a disease or condition would benefit from clarity and alignment on drug development questions, among other factors. In planning each meeting, the foundation must develop a list of medical experts, drug sponsors, scientific organizations, patient organizations, and other entities to be invited to participate. Representatives of the FDA’s review divisions must attend each meeting. After each meeting, the foundation must make available a summary of the meeting noting areas of consensus, areas where additional clarification or information is needed, and next steps agreed upon with the FDA. The bill also requires the FDA to indicate whether it incorporated any input from these meetings when approving a new drug or biologic.
Plain-English rewrite of the Congressional Research Service summary published on Congress.gov. Cached and reviewed.
Subjects
Related legislation
Bills by the same sponsor or covering overlapping subjects.
- HR952Reversionary Interest Conveyance ActPassed House · 2026-10-14
- HR102809–8–8 Implementation Act of 2026Referred to Committee · 2026-09-16
- HR2140Diesel Emissions Reduction Act of 2025Passed House · 2026-09-16
- HRES1525Recognizing September 11, 2026, as a "National Day of Service and Remembrance" and the 25th anniversary of the terrorist attacks of September 11, 2001.Referred to Committee · 2026-09-10